Vidac has built a portfolio of product candidates that target significant unmet medical needs. The value proposition of these novel drugs stems from an unique mechanism of action that offers dermatologists, oncologists and patients both efficacy as well as tolerability.

First-in-Class Portfolio in Dermatology and Oncology image/svg+xml Program Indication Discovery Preclinical POC Phase 1 Phase 2 Phase 3 Dermatology VDA-1102 ointment VDA-1102 ointment SELECTIVE TARGETING OF CANCER CELLS 2019 Actinic Keratosis CTCL Oncology VDA-1102 VDA-1275 Injection Solid Tumors Solid Tumors IMMUNO-METABOLICS Completed 2019 2020 Vidac Pharma for non skin cancer applications VDA 1275 might be developed as a spin off of